Press coverage about Spero Therapeutics (NASDAQ:SPRO) has trended somewhat negative this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spero Therapeutics earned a media sentiment score of -0.06 on Accern’s scale. Accern also assigned news articles about the company an impact score of 48.4418719592987 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several equities research analysts have recently issued reports on the stock. Oppenheimer set a $30.00 price objective on shares of Spero Therapeutics and gave the stock a “buy” rating in a research report on Thursday. Bank of America began coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating for the company. Stifel Nicolaus began coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Cowen began coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They set an “outperform” rating on the stock.
Spero Therapeutics (NASDAQ:SPRO) traded up $0.58 during trading on Thursday, hitting $11.99. 15,900 shares of the stock were exchanged, compared to its average volume of 39,357. Spero Therapeutics has a one year low of $9.84 and a one year high of $15.40. The company has a market cap of $171.86 and a P/E ratio of -4.21.
In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were acquired at an average price of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Joel Sendek acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $70,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 649,356 shares of company stock worth $9,090,984.
COPYRIGHT VIOLATION WARNING: “Somewhat Negative News Coverage Somewhat Unlikely to Impact Spero Therapeutics (SPRO) Share Price” was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.themarketsdaily.com/2018/01/11/somewhat-negative-news-coverage-somewhat-unlikely-to-impact-spero-therapeutics-spro-share-price.html.
Spero Therapeutics Company Profile
SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.